Related Experiment Video

Updated: May 23, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Calming down T cell acute leukemia

Emilio Hirsch1, Roberto Chiarle

  • 1Molecular Biotechnology Center, University of Torino, Torino, Italy. emilio.hirsch@unito.it

Cancer Cell
|April 21, 2012
PubMed

Abstract:

Signaling from class I phosphoinositide 3-kinase (PI3K) is often deregulated in leukemia and lymphoma, but which isoforms are involved in T cell acute lymphoblastic leukemia (T-ALL) was not known. In this issue of Cancer Cell, Subramaniam et al. show that T-ALL can be tamed by inhibiting γ and δ PI3K isoforms.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: May 23, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Articles linked to this work by shared authors, journal, and citation graph.

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights.

British journal of pharmacology·2026

Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.

Frontiers in immunology·2026

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology.

Nature methods·2026

CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma.

Blood·2026

EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

Cancer discovery·2026

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy.

Cancer cell·2026

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.

Cancer cell·2026

Tumor evolution shapes metastatic competence in colorectal cancer.

Cancer cell·2026

TIME in motion: How response takes shape.

Cancer cell·2026

Proteo-genomics-guided interpretation of somatic mutations in cancer genomes.

Cancer cell·2026

Tumor cells recruit macrophage bodyguards to outlast chemotherapy.

Cancer cell·2026

How Much Dissection Is Enough? Mesenteric Vessel Skeletonization Length and Lymph Node Harvest Quality in Rectal Cancer Surgery.

The American surgeon·2026

Follicular lymphoma and the microenvironment: potential targets and biomarkers.

Expert review of clinical immunology·2026

Histotripsy for Hepatocellular Carcinoma: From Bench to Bedside.

Radiology·2026

Targeting the HEC1-NEK2 Axis Suppresses DLBCL Progression and Overcomes Vincristine Resistance.

Molecular cancer therapeutics·2026

KSHV promotes leukocyte adhesion and transendothelial migration via induction of VCAM1.

mBio·2026

Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling.

Cancer reports (Hoboken, N.J.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us